SET7-IN-DC21
SET7-IN-DC21 is a selective, potent SET7 inhibitor (IC50 = 15.93 μM; KD = 18.00 μM). SET7-IN-DC21 has good selectivity for several other epigenetic targets, such as SUV39H1, G9a, NSD1, DOT1L and MOF. SET7-IN-DC21 can be used for the researches of cancer, infection, inflammation, metabolic and cardiovascular disease, such as breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 2567886-53-5
- Formula: C12H8O5
- Molecular Weight:232.19
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Histone Methyltransferase Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
25.84 μM
Compound: DC21
|
Antiproliferative activity against human MCF7 cells expresses endogenous ER by Cell Titer-Glo based luminescence assay
Antiproliferative activity against human MCF7 cells expresses endogenous ER by Cell Titer-Glo based luminescence assay
|
[PMID: 32173197] |
In Vitro
SET7-IN-DC21 (0.5-2.5 μM, 72 h) inhibits the proliferation of MCF7 cells in a dose-dependent manner (IC50 = 25.84 μM), and has little effect on the proliferation of normal cells, including normal embryonic lung fibroblast cell line MRC-5 and umbilical vascular endothelial cell line HUV-EC-C[1].
SET7-IN-DC21 (6.25-200 μM, 72 h) can decrease the stability of ERα, which leads to a decrease in ERα protein level in the MCF7 cell line in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF7 cells, HUV-EC-C cells, MRC-5 cells
-
Concentration:0.5 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM
-
Incubation Time:72 h
-
Result:Inhibited the proliferation of MCF7 cells in a dose-dependent manner (IC50 = 25.84 μM), and had little effect on the proliferation of normal cells, including normal embryonic lung fibroblast cell line MRC-5 and umbilical vascular endothelial cell line HUV-EC-C.
-
Cell Line:MCF7 cells
-
Concentration:6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM, 200 μM
-
Incubation Time:72 h
-
Result:Dose-dependently reduced the protein expression level of estrogen receptor α (ERα) in MCF7 cells.
Chemical Information
-
CAS No. 2567886-53-5
-
Molecular Weight 232.19
-
Formula C12H8O5
-
SMILES
O=C(C=C1)C(C2=CC=C(C(OC)=O)O2)=CC1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)